製品番号: HY-N0280

コロソリン酸

(別名: Corosolic acid; Colosolic acid)

4 Cited Publications

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Corosolic acid (Colosolic acid) isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity. Corosolic acid induces cancer cell apoptosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.89%
CAS 番号: 4547-24-4
分子式: C₃₀H₄₈O₄
分子量:472.70

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Corosolic acid 構造式

CAS 番号: 4547-24-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (4)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Corosolic acid (Colosolic acid) isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity. Corosolic acid induces cancer cell apoptosis^[1]^[2]^[3].

EGFR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	>100 μM Compound: 21	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
BV-2	IC₅₀	47.1 μM Compound: 12	Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay	[PMID: 28358502]
CCRF-CEM	IC₅₀	3.27 μM Compound: 14	Cytotoxicity against human CEM cells after 48 hrs Cytotoxicity against human CEM cells after 48 hrs	[PMID: 20873721]
H9	EC₅₀	4 μg/mL Compound: 7	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	IC₅₀	8 μg/mL Compound: 7	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
HCT-116	GI₅₀	>100 μM Compound: 21	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HEK293	IC₅₀	0.81 μM Compound: 1	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting	[PMID: 20100662]
HepG2	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HT-29	IC₅₀	>10 μM Compound: 14	Cytotoxicity against human HT-29 cells after 48 hrs Cytotoxicity against human HT-29 cells after 48 hrs	[PMID: 20873721]
MCF7	GI₅₀	18.5 μM Compound: Corosolic acid	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	GI₅₀	62 μM Compound: 21	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	>10 μM Compound: 14	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 20873721]
MCF7	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MDA-MB-231	GI₅₀	15.3 μM Compound: Corosolic acid	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
NCI-H460	IC₅₀	>10 μM Compound: 14	Cytotoxicity against human NCI-H460 cells after 48 hrs Cytotoxicity against human NCI-H460 cells after 48 hrs	[PMID: 20873721]
NCI-N87	IC₅₀	4.4 μM Compound: 23	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
Sf21	IC₅₀	>40 μM Compound: 24	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
SK-OV-3	IC₅₀	10.51 μM Compound: 1	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 35500202]
SK-OV-3	IC₅₀	26.42 μM Compound: 1	Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM) Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)	[PMID: 35500202]

体外実験

Corosolic acid shows cytotoxicity for Hep G2, A549, SNU-C4, HeLa, K-562 cells, with ED₅₀s of 0.4-5.0 μg/mL^[1].
Corosolic acid (0-50 μg/mL) inhibits PKC activity in a dose-dependent way^[1].
Corosolic acid (0-50 μM, 6-24 h) induces apoptosis and increases cells in the sub-G1 population in CT-26 cells^[3].
Corosolic acid (20 μM, 0-24 h) inhibits HER2/HER3 heterodimerization and phosphorylation of HER2 and HER3 in HCT116 and SW480 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[3]

Cell Line:

CT-26 cells
Concentration:

25 µM
Incubation Time:

12 and 24 h
Result:

Increased cleaved caspase-3 level.
Increased cells in the sub-G1 population.
Increased fluorescin-dUTP labeling DNA strand breaks.

Western Blot Analysis^[5]

Cell Line:

HCT116 and SW480 cells
Concentration:

20 μM
Incubation Time:

0-24 h
Result:

Decreased the formation of NRG1-induced HER2/HER3 heterodimer.
Inhibited the PI3K/Akt/PDE3B but not the ERK1/2 signaling pathway.

体内実験

Corosolic acid (5, 25 mg/kg/day, peritumor injection, 12 days) inhibits tumor growth and shows anti-angiogenic effect in CT-26 allograft colon carcinoma mice model^[3].
Corosolic acid (10 and 20 mg/kg, i.p., every 2 days) inhibits tumor growth in a murine PC-3 xenograft model by activating ER stress^[4].
Corosolic acid (10 mg/kg/d, supplemented in diet, 8 weeks) inhibits adipose tissue inflammation, and improves insulin resistance via AMPK activation in high-fat fed mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CT-26 allograft colon carcinoma mice model^[3]
Dosage:

5, 25 mg/kg/day
Administration:

Peritumor injection, 12 days
Result:

Reduced the tumor weight to 76.2% and 53.8% of the control group.
Reduced blood and lymphatic vessel densities.

Animal Model:

high-fat fed mice^[6]
Dosage:

10 mg/kg/day
Administration:

Supplemented in diet, 8 weeks
Result:

Inhibited hyperlipidemia, Improved insulin sensitivity and glucose intolerance.
Inhibited inflammation in adipose tissues.
Inhibited macrophage infiltrations into adipose tissue.

化学情報

CAS 番号 4547-24-4
性状 Solid
分子量 472.70
分子式 C₃₀H₄₈O₄
Color White to off-white
SMILES

O[C@H]1[C@H](O)C(C)(C)[C@@](CC[C@]2(C)[C@]3([H])CC=C4[C@@]2(C)CC[C@]5(C(O)=O)[C@@]4([H])[C@@H](C)[C@H](C)CC5)([H])[C@]3(C)C1
別名

Corosolic acid; Colosolic acid
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All Cell Proliferation/Viability AssayCell Imaging/StainingFlow CytometryRT-PCRWB

Sort by:

Journal Impact Factor

Cancer Drug Resist

Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis. [Abstract]

2025 Aug 7:8:40. PMID: 40843357

Corosolic acid purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Aug 7:8:40. [Abstract]

AGS and MKN-45 cells were exposed to different concentrations of Corosolic acid (CA) (0, 2, 5, 10, 20, and 40 μm) for 24 h, and cell viability was measured using CCK-8.

Corosolic acid purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Aug 7:8:40. [Abstract]

AGS-CR cells were treated with 5 µM of Corosolic acid (CA) and 35 µM of Cisplatin for 3 days, and then clone formation assay.

Corosolic acid purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Aug 7:8:40. [Abstract]

AGS-CR cells were treated with 5 µM of Corosolic acid (CA) and 35 µM of Cisplatin for 24 h, after which flow cytometry.

Corosolic acid purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Aug 7:8:40. [Abstract]

AGS cells were treated with 5 µM of Corosolic acid (CA) for 24 h, and the mRNA levels of Gpx4, Ptgs2, Acsl4, Fth1, Nox1, and Slc7a11 were assessed using qRT-PCR.

Corosolic acid purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Aug 7:8:40. [Abstract]

AGS cells were treated with 5 µM of Corosolic acid (CA) for 24 h, and the protein levels of Gpx4, Ptgs2, Acsl4, Fth1, Nox1, and Slc7a11 were assessed using western blot.
Chin Med

Integration of network pharmacology, transcriptomics and single-cell sequencing to explore the effect of Rougan Keli in alleviating liver cirrhosis. [Abstract]

2025 Oct 2;20(1):153. PMID: 41039598
Sci Rep

Corosolic acid alleviates rheumatoid arthritis by down regulation of the NF-κB/PI3K/AKT signaling pathway. [Abstract]

2026 Mar 28;16(1):10760. PMID: 41904314
iScience

Corosolic acid attenuates cardiac ischemia/reperfusion injury through the PHB2/PINK1/parkin/mitophagy pathway. [Abstract]

2024 Jul 8;27(8):110448. PMID: 39091464

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (52.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1155 mL

10.5775 mL

21.1551 mL

5 mM

0.4231 mL

2.1155 mL

4.2310 mL

10 mM

0.2116 mL

1.0578 mL

2.1155 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (5.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ahn KS, et al. Corosolic acid isolated from the fruit of Crataegus pinnatifida var. psilosa is a protein kinase C inhibitor as well as a cytotoxic agent. Planta Med. 1998 Jun;64(5):468-70. [Content Brief]

[2]. LI Biao, et al. Mechanism of antitumor action of corosolic acid. China Journal of Modern Medicine, 2015-08

[3]. Ki Hyun Yoo, et al. Corosolic Acid Exhibits Anti-angiogenic and Anti-lymphangiogenic Effects on In Vitro Endothelial Cells and on an In Vivo CT-26 Colon Carcinoma Animal Model. Phytotherapy Research, 2015 , 29 (5): 14–723

[4]. Ma B, et al. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3. J Exp Clin Cancer Res. 2018 Sep 3;37(1):210. [Content Brief]

[5]. Zhang BY, et al. Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor. Br J Pharmacol. 2021 Mar;178(6):1475-1491. [Content Brief]

[6]. Yang J, et al. Corosolic acid inhibits adipose tissue inflammation and ameliorates insulin resistance via AMPK activation in high-fat fed mice. Phytomedicine. 2016 Feb 15;23(2):181-90. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1155 mL	10.5775 mL	21.1551 mL	52.8877 mL
	5 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	10 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	15 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	20 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	25 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	30 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	40 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	50 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL

Keywords

Corosolic acid

4 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

コロソリン酸

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Corosolic acid

EGFR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Corosolic acid 関連分類

HY-N0280 関連分類